A phase III trial of efficacy of the FML-vaccine against canine kala-azar in an endemic area of Brazil (São Gonçalo do Amaranto, RN)

Vaccine. 2000 Dec 8;19(9-10):1082-92. doi: 10.1016/s0264-410x(00)00339-x.

Abstract

Protection against canine kala-azar was investigated in naturally exposed dogs of an endemic area, vaccinated with the fucose mannose ligand (FML)-vaccine of Leishmania donovani. A total of 97% of vaccinees were seropositive to FML and 100% showed intradermal reaction to L. donovani lysate, 7 months after vaccination. The absorbency values and size of intradermal reaction were both significantly higher in vaccinees than in controls (ANOVA, P<0.0001). After 2 years, 92% (chi(2)=6.996; P<0.0025) protection was achieved: only 8% of vaccinees showed mild signs of kala-azar with no deaths while 33% of controls developed clinical or fatal disease. The FML-vaccine induced a significant, long-lasting and strong protective effect against canine kala-azar in the field.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Brazil
  • Dogs
  • Lectins / immunology*
  • Leishmania donovani / immunology*
  • Leishmaniasis, Visceral / prevention & control*
  • Protozoan Vaccines / immunology*
  • Vaccination
  • Zoonoses

Substances

  • Lectins
  • Protozoan Vaccines
  • fucose-binding lectin